David R. Magnin

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau, Richard E. Gregg, Thomas Harrity et al. · Science · 1998 · 269 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)

Richard Sulsky, David R. Magnin, Yanting Huang et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 151 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability:  Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-<scp>l</scp>-<i>cis</i>-4,5-methanoprolinenitrile-Based Inhibitors

David R. Magnin, Jeffrey A. Robl, Richard Sulsky et al. · Journal of Medicinal Chemistry · 2004 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo.

Carl P. Ciosek, David R. Magnin, Thomas Harrity et al. · Journal of Biological Chemistry · 1993 · 102 citations · Full text

Life Sciences, Biochemistry, Pharmacology +16